Novel regimens and delivery systems in the pharmacological treatment of Alzheimer's disease.
about
Latrepirdine for Alzheimer's diseaseDimebon for Alzheimer's diseaseThe flavonoid quercetin ameliorates Alzheimer's disease pathology and protects cognitive and emotional function in aged triple transgenic Alzheimer's disease model miceDementia, Preclinical Studies in Neurodegeneration and its Potential for Translational Medicine in South AmericaCurrent and emerging drug treatment options for Alzheimer's disease: a systematic review.sym-Triazines for directed multitarget modulation of cholinesterases and amyloid-β in Alzheimer's disease.A 24-week, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety and tolerability of the rivastigmine patch in Japanese patients with Alzheimer's disease.Donepezil combined with natural hirudin improves the clinical symptoms of patients with mild-to-moderate Alzheimer's disease: a 20-week open-label pilot studyMemantine as an augmentation therapy for anxiety disorders.A 24-Week, Randomized, Controlled Study to Evaluate the Tolerability, Safety and Efficacy of 2 Different Titration Schemes of the Rivastigmine Patch in Japanese Patients with Mild to Moderate Alzheimer's DiseaseLinalool reverses neuropathological and behavioral impairments in old triple transgenic Alzheimer's mice.Gene Therapy Models of Alzheimer's Disease and Other Dementias.Characteristics of patients with Alzheimer's disease who switch to rivastigmine transdermal patches in routine clinical practice.An overview of investigational antiapoptotic drugs with potential application for the treatment of neurodegenerative disorders.Memantine ER, a once-daily formulation for the treatment of Alzheimer's disease.Neuroimmune pharmacology of neurodegenerative and mental diseases.Drug delivery strategies for Alzheimer's disease treatment.Rivastigmine transdermal patch: a review of its use in the management of dementia of the Alzheimer's type.Functional proteomics: application of mass spectrometry to the study of enzymology in complex mixtures.Cholinesterase inhibitor adjunctive therapy for cognitive impairment and depressive symptoms in older adults with depression.Transdermal rivastigmine in the treatment of Alzheimer's disease: current and future directions.Rivastigmine from capsules to patch: therapeutic advances in the management of Alzheimer's disease and Parkinson's disease dementia.PROTECTIVE EFFECT OF IRIS GERMANICA L. IN Β-AMYLOID-INDUCED ANIMAL MODEL OF ALZHEIMER'S DISEASE.Recent trends in the transdermal delivery of therapeutic agents used for the management of neurodegenerative diseases.Transdermal donepezil on the treatment of Alzheimer's disease.Transdermal is better than oral: observational research of the satisfaction of caregivers of patients with Alzheimer's disease treated with rivastigmine.Acupuncture for patients with mild to moderate Alzheimer's disease: a randomized controlled trial.Clinical compliance of donepezil in treating Alzheimer's disease in taiwan.Amelioration of amyloid β-induced cognitive deficits by Zataria multiflora Boiss. essential oil in a rat model of Alzheimer's disease.A 24-week, multicentre, open evaluation of the clinical effectiveness of the rivastigmine patch in patients with probable Alzheimer's disease.UHPLC-ESI-ORBITRAP-MS analysis of the native Mapuche medicinal plant palo negro (Leptocarpha rivularis DC. - Asteraceae) and evaluation of its antioxidant and cholinesterase inhibitory properties.Impact of transdermal drug delivery on treatment adherence in patients with Alzheimer’s disease
P2860
Q24186444-4CA88605-EBAA-4B90-8608-1E783D4A1E25Q24234998-D89F715C-8C83-4A9D-BF02-E92B22224CDDQ27305145-23A47686-02D0-45BD-AB94-0446152F81A1Q28817091-968944BF-00A4-4335-97B8-C36AC5256C34Q34222721-C777D8A2-5AF9-4A1E-96C6-BD75F46A8C81Q34591673-C51FD4C1-3ADD-45E8-AEDC-8D2C9F3A72FFQ35428213-7A453F71-4FDE-4198-B76B-EC9292768AD9Q35966108-38FDCE4B-A8A4-4663-A250-65C7CD4890EFQ36169059-2E937344-A798-4246-8914-6A6B86816AE9Q36261229-D1DC8718-3000-46F4-9FB4-9C87FCA7D693Q36421740-33A705CE-D39F-436F-989B-7E38BABFA3B8Q36524290-8892333E-391E-46DC-B66C-81BFB794C650Q36538811-16F506AF-777E-4FCD-B385-15CD1C943888Q37733587-950E81A6-0FBF-46C6-90E5-3F32EF0C7867Q37764347-128B7D97-47EA-4239-AED3-27D26947EAABQ37785813-CE1043FD-9CB3-4E5D-8FE0-A93625E447CAQ37851509-B3007CE3-8B2A-43F5-948D-F53D9272C970Q37895257-5DD064A2-9907-4182-B2F9-2AA8EF253A7BQ37902554-0B8B5FFB-D547-439D-993E-79A34E791F76Q37993335-55A1BEE4-5CFC-4971-AB65-8862BFF013C2Q38247181-F8C46DE6-E0ED-4086-8636-A2AED5169E9BQ38350602-A83089F9-41DB-45FD-B93F-C9A9283DC8DBQ38714669-49BCAD10-82B5-4475-8518-6EBA0F5DD64BQ38972042-7781350D-294D-40E7-A817-8DB2DC92F1F8Q41786451-E406A5BB-F48B-4AEE-89DC-BD06783D3655Q45803280-2DE850F8-045C-4271-92AD-F9579705CA02Q47144083-301D9B8B-8768-4AE8-BEAF-F9C62DDA928CQ50614178-E55AFF0C-1910-42C6-A74B-445E7E10801FQ50780400-415317BC-7380-4F19-A69E-9A20A12D07EAQ50799612-29C59A28-8CFE-43E8-9FC1-EE9A9550B5A8Q55560280-532C8350-3B6A-4853-8CC4-CA89197429F9Q57814526-64E25607-2BB3-4CF2-BAD7-9FCA8723546B
P2860
Novel regimens and delivery systems in the pharmacological treatment of Alzheimer's disease.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Novel regimens and delivery sy ...... atment of Alzheimer's disease.
@en
Novel regimens and delivery sy ...... atment of Alzheimer's disease.
@nl
type
label
Novel regimens and delivery sy ...... atment of Alzheimer's disease.
@en
Novel regimens and delivery sy ...... atment of Alzheimer's disease.
@nl
prefLabel
Novel regimens and delivery sy ...... atment of Alzheimer's disease.
@en
Novel regimens and delivery sy ...... atment of Alzheimer's disease.
@nl
P2860
P1433
P1476
Novel regimens and delivery sy ...... atment of Alzheimer's disease.
@en
P2093
George T Grossberg
Nazem Bassil
P2860
P304
P356
10.2165/00023210-200923040-00003
P577
2009-01-01T00:00:00Z
P6179
1009996428